Jay T. Flatley — Executive Chairman at Illumina

Mr. Jay T. Flatley has been an Executive Chairman of Illumina, Inc. since July 5, 2016. Mr. Flatley served as the Chief Executive Officer of Illumina, Inc. from October 1999 to July 5, 2016 and also served as its President from October 1999 to December 2, 2013, where he oversaw its expansion into the whole genome sequencing area with the acquisition of Solexa in 2006. He was a Co-Founder of Molecular Dynamics, Inc. and served as its Vice President of Operations from September 1987 to January 1990. He also served as the Chief Operating Officer and Senior Vice President at Molecular Dynamics. He served as the President of Molecular Dynamics, Inc. since August 1991 and its Chief Executive Officer since July 1994 and Acting Chief Financial Officer since October 28, 1994. While at Molecular Dynamics, he was the primary interface with financial analysts and investors, leading its IPO in 1993 and its sale to Amersham Pharmacia Biotech in 1998. Under his direction, it developed and launched over 15 major instrumentation systems including the world's first capillary-based DNA sequences. He served in various other positions with Molecular Dynamics from 1987 to 1994. From 1985 to 1987, he served as Vice President of Engineering and Vice President of Strategic Planning at Plexus Computers, a UNIX computer company. He served as an Executive Vice President for Manning Technologies and held various manufacturing positions at the Autolab division of Spectra Physics. He Chairs the Board of Directors for an Illumina subsidiary, Helix. He served as the Chairman and Director of GRAIL, Inc. He served as the Chairman of Illumina, Inc. from January 28, 2016 to July 5, 2016 and has been Director since October 1999. He has been a Director of Juno Therapeutics, Inc. since May 23, 2017 and Coherent, Inc. since 2011. He serves as a Director of Helix Holdings I, LLC and Denali Therapeutics Inc. since April 2015. He serves as a Director at the Keck Graduate Institute Board of Trustees. He serves as a Board of Trustees of the Salk Institute. He served as a Director of Bruker AXS, Inc. since November 2000, Genvault Corporation, Helixis, Inc. since February 2009 and Molecular Dynamics, Inc. from March 1992 to September 1999. He serves as an Advisory Board Member for UC San Diego's Moores Cancer Center. Mr. Flatley holds a B.A. in Economics from Claremont McKenna College and a B.S. and M.S. in Industrial Engineering from Stanford University.